BOSTON, Dec. 5, 2019 /PRNewswire-PRWeb/ -- Concerto HealthAI announced today that Craig White, PhD, has joined the company as Senior Vice President and General Manager of Outcomes Science and Services (OS&S). Dr. White brings more than 20 years of in health economic outcomes, market access, and clinical development studies.
In recent years, Concerto HealthAI has emerged as the leader in Real-World Data (RWD) and AI technology solutions for precision oncology. The company's singular mission is to transform healthcare by revolutionizing research models, accelerate insights benefitting patients, and bringing an array of solutions supporting the entire patient treatment journey.
Concerto HealthAI's Outcomes Sciences group is pioneering industry-leading Real-world Data (RWD)nretrospective and prospective studies and bringing RWD to regulatory submissions as External Control Arms and post-approval RWD studies with potential regulatory intent. In the coming months, Concerto HealthAI will be integrating its RWD products and eurekaHealth 3.0 solution into OS&S to provide predictive models, virtual registries, and a novel "subscription study" model for HEOR and epidemiological studies.
"Craig is a forward-focused leader, who brings a valuable combination of deep experience and relentlessness to find meaningful and actionable insights that can accelerate needed therapeutic innovations for patients' highest unmet needs," said Jeff Elton, PhD and CEO of Concerto HealthAI. "As we look towards the future catalyzed by the 21st Century Cures Act and the recent FDA encouragement to advance RWD as part of submissions and to inform study designs, I am excited to have Craig as a key member of our team."
Previously, Dr. White held leadership roles at Precision Medicine Group, where he was Vice President and Managing Director of the Health Economics and Outcomes Research group. Prior to that, he was at IQVIA where he served on the Enterprise Solutions Team for Real World Insights and led marquee initiatives in digital health and value-based pricing. Dr. White has a PhD in Health Policy from Harvard University and a BE in Electrical and Electronic Engineering from the University of Auckland.
"Concerto HealthAI has emerged as the leader in developing previously unavailable RWD solutions and matching these to the latest data science insights tools," said Dr. White. "My entire career has been focused on accelerating the clinical development process and advancing lifesaving medicines more quickly and efficiently. I'm privileged and thrilled to be joining the Concerto HealthAI team at this pivotal time, and excited about the possibilities."
About Concerto HealthAI Concerto HealthAI is a technology leader in Definitive Real-World Data (RWD) and AI solutions for precision oncology. Our mission is to bring together unique data assets, leading AI-based technologies, and the world's top outcomes research and data science talent. Our focus is on revolutionizing clinical and outcomes research to accelerate the insights benefitting patient treatment. Concerto HealthAI is a SymphonyAI Group company. eurekaHealth is a trademark of Concerto HealthAI. For more information, visit us at http://www.concertohealthai.com.
About SymphonyAI Group SymphonyAI Group is the fastest-growing private group of B2B AI companies, backed by a $1 billion commitment to deliver next-generation AI solutions for transforming the enterprise. Since its founding in 2017, SymphonyAI Group has grown rapidly to a group of six companies with a combined revenue run rate approaching $300 million. Over 1,600 talented leaders, data scientists, and other professionals operate the group under the leadership of one of Silicon Valley's most successful serial entrepreneurs, Dr. Romesh Wadhwani. Website: http://www.symphonyai.com
Media Contact: Jennifer Toole 617-779-1828 [email protected]
SOURCE Concerto HealthAI
Advertisement
In recent years, Concerto HealthAI has emerged as the leader in Real-World Data (RWD) and AI technology solutions for precision oncology. The company's singular mission is to transform healthcare by revolutionizing research models, accelerate insights benefitting patients, and bringing an array of solutions supporting the entire patient treatment journey.
Advertisement
Concerto HealthAI's Outcomes Sciences group is pioneering industry-leading Real-world Data (RWD)nretrospective and prospective studies and bringing RWD to regulatory submissions as External Control Arms and post-approval RWD studies with potential regulatory intent. In the coming months, Concerto HealthAI will be integrating its RWD products and eurekaHealth 3.0 solution into OS&S to provide predictive models, virtual registries, and a novel "subscription study" model for HEOR and epidemiological studies.
"Craig is a forward-focused leader, who brings a valuable combination of deep experience and relentlessness to find meaningful and actionable insights that can accelerate needed therapeutic innovations for patients' highest unmet needs," said Jeff Elton, PhD and CEO of Concerto HealthAI. "As we look towards the future catalyzed by the 21st Century Cures Act and the recent FDA encouragement to advance RWD as part of submissions and to inform study designs, I am excited to have Craig as a key member of our team."
Previously, Dr. White held leadership roles at Precision Medicine Group, where he was Vice President and Managing Director of the Health Economics and Outcomes Research group. Prior to that, he was at IQVIA where he served on the Enterprise Solutions Team for Real World Insights and led marquee initiatives in digital health and value-based pricing. Dr. White has a PhD in Health Policy from Harvard University and a BE in Electrical and Electronic Engineering from the University of Auckland.
"Concerto HealthAI has emerged as the leader in developing previously unavailable RWD solutions and matching these to the latest data science insights tools," said Dr. White. "My entire career has been focused on accelerating the clinical development process and advancing lifesaving medicines more quickly and efficiently. I'm privileged and thrilled to be joining the Concerto HealthAI team at this pivotal time, and excited about the possibilities."
About Concerto HealthAI Concerto HealthAI is a technology leader in Definitive Real-World Data (RWD) and AI solutions for precision oncology. Our mission is to bring together unique data assets, leading AI-based technologies, and the world's top outcomes research and data science talent. Our focus is on revolutionizing clinical and outcomes research to accelerate the insights benefitting patient treatment. Concerto HealthAI is a SymphonyAI Group company. eurekaHealth is a trademark of Concerto HealthAI. For more information, visit us at http://www.concertohealthai.com.
About SymphonyAI Group SymphonyAI Group is the fastest-growing private group of B2B AI companies, backed by a $1 billion commitment to deliver next-generation AI solutions for transforming the enterprise. Since its founding in 2017, SymphonyAI Group has grown rapidly to a group of six companies with a combined revenue run rate approaching $300 million. Over 1,600 talented leaders, data scientists, and other professionals operate the group under the leadership of one of Silicon Valley's most successful serial entrepreneurs, Dr. Romesh Wadhwani. Website: http://www.symphonyai.com
Media Contact: Jennifer Toole 617-779-1828 [email protected]
SOURCE Concerto HealthAI
